Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube..
Research and Financial Data on Unicycive Therapeutics
Please complete the form below to submit your registration request for Unicycive Therapeuticss Virtual One-on-One Meeting, to be held October 9, 2024 via Zoom, presented by Noble Capital Markets. This meeting is open to qualified investors, and offered at no cost.
A representative will contact you, using the information you provide below, with more details on attending the event.
© 2023 Noble Capital Markets, Inc.
Noble Capital Markets, Inc. Members FINRA, SIPC, MSRB